© Katie Chizhevskaya (AdobeStock)
© Medizin Foto Köln
© Medizin Foto Köln
Prof. Dr. Roman-Ulrich Müller, Professor of Translational Nephrology and spokesperson for the Center for Rare and Hereditary Kidney Diseases (ZSEN), has received funding from the German Research Foundation (DFG) for a multicentre drug trial. The STOP-PKD study, coordinated jointly with Dr. Philipp Scherrer, will investigate the use of SGLT2 inhibitors in patients with autosomal dominant polycystic kidney disease (ADPKD).
ADPKD is a genetic disease that leads to the development of large cystic kidneys and progressive loss of kidney function. Patients usually require some form of renal replacement therapy (dialysis, kidney transplant) by the age of 50 to 60. SGLT2 inhibitors have become an indispensable part of medicine, significantly improving the prognosis not only of chronic kidney disease but also of diabetes and heart failure. Until now, patients with ADPKD have been excluded from registration trials for the treatment of chronic kidney disease. As there are very limited treatment options for ADPKD, the STOP-PKD study aims to evaluate the safety and efficacy of SGLT2 inhibitors in adults with ADPKD. The investigator-initiated study will be conducted as a randomized, placebo-controlled, double-blind, multicenter trial with the highest quality standards at 18 German and six European sites. The DFG is supporting the six-year project of Prof. Müller and his team with more than three million euros in the first three years. Follow-up funding for the next three years is already planned.
Media Contact:
Professor Dr. Roman-Ulrich Müller
CECAD Cluster of Excellence for Aging Research
+49 221 478 3439
roman-ulrich.mueller[at]uk-koeln.de
Press and Communications Team:
Mirko Ristau
Deputy Press Spokesperson
University Hospital Cologne
+49 221 478 5548 and +49 152 54695952
presse[at]uk-koeln.de
English Adaptation:
Dr. Tanio Calabrese
+49 221 478 84044
g.calabrese[at]uni-koeln.de
Source: